These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20920857)

  • 21. Growth factor frenzy.
    Quesenberry PJ
    Exp Hematol; 1993 Jul; 21(7):835-6. PubMed ID: 7686499
    [No Abstract]   [Full Text] [Related]  

  • 22. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
    Rajan SS; Lyman GH; Stearns SC; Carpenter WR
    Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase.
    Iqbal MP; Burney IA
    Pak J Pharm Sci; 2014 Mar; 27(2):245-8. PubMed ID: 24577909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulocyte macrophage colony-stimulating factor: current practice and novel approaches.
    Buchsel PC; Forgey A; Grape FB; Hamann SS
    Clin J Oncol Nurs; 2002; 6(4):198-205. PubMed ID: 12087615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte-macrophage colony-stimulating factor in neutropenia.
    Hogan KR; Peters MD
    DICP; 1991 Jan; 25(1):32-5. PubMed ID: 2008785
    [No Abstract]   [Full Text] [Related]  

  • 29. Biosimilar medicines used for cancer therapy in Europe: a review.
    Santos SB; Sousa Lobo JM; Silva AC
    Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Present and future indications of G-CSF in breast cancer].
    Chevallier B
    Pathol Biol (Paris); 1993 Jan; 41(1):47. PubMed ID: 7686285
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What do oncologists need to know about biosimilar products?
    Leung LK; Mok K; Liu C; Chan SL
    Chin J Cancer; 2016 Oct; 35(1):91. PubMed ID: 27733189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of neutropenia in HIV infection with hematopoietic growth factors].
    Moreno García M; Fernández González F
    Rev Clin Esp; 1996 Apr; 196(4):248-54. PubMed ID: 8701065
    [No Abstract]   [Full Text] [Related]  

  • 35. [Small cell lung cancer: value of G-CSF].
    Trillet V
    Pathol Biol (Paris); 1993 Jan; 41(1):46. PubMed ID: 7686284
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
    Lyman GH
    J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of granulocyte colony-stimulating factor (G-CSF) on the activity of granulocyte enzymes in children with cancer who developed neutropenia after chemotherapy.
    Czygier M; Dakowicz L; Szmitkowski M
    Adv Med Sci; 2008; 53(2):278-82. PubMed ID: 18614436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors.
    Morstyn G; Sheridan W; Lieschke G; Cebon J; Layton J; Fox R
    Prog Clin Biol Res; 1990; 354B():29-36. PubMed ID: 1700441
    [No Abstract]   [Full Text] [Related]  

  • 40. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.